The pilot study of Liraglutide (Victoza), a GLP-1 agonist, aims to assess its efficacy in reducing parenteral support requirements in patients with short bowel syndrome. This indication represents a niche but potentially lucrative market, given the limited treatment options for short bowel syndrome. The failure to recruit participants due to COVID-19 highlights the challenges in conducting clinical trials during global health crises, which may impact timelines and investor confidence. The competitive landscape includes other GLP-1 agonists and novel therapies targeting gastrointestinal disorders, necessitating a thorough diligence process to evaluate market positioning and potential partnerships.